Mesoblast Financial Results and Corporate Update
Mesoblast Limited (NASDAQ: MESO; ASX: MSB) is at the forefront of developing allogeneic cellular medicines targeted at treating inflammatory diseases. The company is hosting a webcast to provide insights into its operational highlights and the financial results for the year ending June 30, 2024.
Details of the Webcast
The webcast is scheduled to begin at 6:30 PM EDT, offering an in-depth look at the company's progress during the previous fiscal year. You can access the webcast for detailed information about the company’s performance and growth indicators.
About Mesoblast's Innovation in Cellular Medicine
Mesoblast has established itself as a leader in allogeneic (off-the-shelf) cellular therapies for serious inflammatory conditions. Their proprietary mesenchymal lineage cell therapy technology is pivotal in their expansive portfolio, which includes various late-stage product candidates. These therapies are designed to counteract severe inflammation by releasing anti-inflammatory factors, thereby modulating the immune system's response, which ultimately helps reduce the damaging effects of inflammation.
Global Intellectual Property and Manufacturing Processes
The company possesses a robust global intellectual property portfolio, providing protection until at least 2041 across all major markets. Mesoblast's proprietary manufacturing methods facilitate the production of industrial-scale, cryopreserved cellular medicines that are designed for off-the-shelf availability for patients around the globe.
Development of Unique Product Candidates
Mesoblast is working on several product candidates leveraging its advanced remestemcel-L and rexlemestrocel-L platforms. Remestemcel-L aims to address inflammatory diseases in both children and adults, particularly conditions like steroid-refractory acute graft versus host disease and biologic-resistant inflammatory bowel disease. Meanwhile, rexlemestrocel-L targets advanced chronic heart failure and chronic low back pain. Some of these products have already been commercialized in Japan and Europe through strategic partnerships.
Commercial Partnerships and Future Prospects
The company continues to establish commercial collaborations in Europe and China, driving forward its Phase 3 assets. With its extensive network and innovative approach, Mesoblast is positioning itself to make significant inroads in the global market for cellular therapies.
Company Overview and Contact Information
With operational bases in Australia, the United States, and Singapore, Mesoblast is publicly listed on both the Australian Securities Exchange (ASX: MSB) and the Nasdaq (NASDAQ: MESO). The company remains committed to advancing its revolutionary cellular medical technologies and expanding its market reach.
For further information, you can contact:
Corporate Communications / Investors:
Paul Hughes
T: +61 3 9639 6036
E: investors@mesoblast.com
Media:
Steve Dabkowski
T: +61 419 880 486
E: steve@bluedot.net.au
Frequently Asked Questions
What is the purpose of the Mesoblast webcast?
The webcast aims to discuss operational highlights and the financial results of Mesoblast for the fiscal year ended June 30, 2024.
What are the key product platforms developed by Mesoblast?
Mesoblast's key product platforms include remestemcel-L and rexlemestrocel-L, focusing on treating severe inflammatory conditions and other critical diseases.
Where can I find archived information about the webcast?
The archived webcast can be accessed on Mesoblast's Investor page once it is available.
What markets are Mesoblast's products targeting?
Mesoblast targets major markets globally, including regions in Asia, Europe, and North America, focusing on severe inflammatory conditions.
How can I contact Mesoblast for more information?
For corporate communications or investor inquiries, you can reach Paul Hughes at +61 3 9639 6036 or via email at investors@mesoblast.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Perseus Mining Reports Strong Financial Performance
- Biologics Market Growth: Key Insights and Future Trends
- Aircraft Refurbishing Market Growth and Insights
- American Lithium Corp: Leadership Changes and Strategy Update
- Acri Capital Acquisition Corporation and Foxx Development's Strategic Merger
- NextGen Food Robotics Updates on MCTO and Business Progress
- Waldencast Reports Strong Q2 2024 Financial Results
- Gran Tierra Energy Inc. Updates on i3 Energy Acquisition
- Ingersoll Rand Highlights Participation in Investor Conferences
- Cipher Mining Expands Data Center Operations with New Site